Midkine Promoter Can Mediate Transcriptional Activation of a Fused Suicide Gene in a Broader Range of Human Breast Cancer Compared with c-erbB-2 Promoter
Authors:
- Naohito YamamotoNYNaohito Yamamoto
- Kenji KadomatsuKKKenji Kadomatsu
- Takashi MuramatsuTMTakashi Muramatsu
- Shuichiro MatsubaraSMShuichiro Matsubara
- Shigeru SakiyamaSSShigeru Sakiyama
- Masatoshi TagawaMTMasatoshi Tagawa
- 1 May 2004
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 66 (2) , 143-149
Abstract
We examined the expression level of the midkine (MK) and c-erbB-2 genes in both tumorous and matched nontumorous specimens from 18 patients with breast cancer. Expression of the MK and c-erbB-2 genes in nontumorous regions was relatively low, and the expression levels of both genes were not markedly different among the nontumorous samples. In contrast, the expression of the MK and c-erbB-2 genes in tumorous specimens was upregulated in 18 and 6 specimens, respectively. Regulatory regions of the MK gene were able to activate a reporter gene to a similar degree as those of the c-erbB-2 gene in the human breast cancer cell lines tested. Transfection of breast cancer cells with either the MK promoter- or the c-erbB-2 promoter-linked herpes simplex virus thymidine kinase gene increased their sensitivity to the prodrug ganciclovir. These data showed that the MK promoter activated a therapeutic gene in a wider range of human breast cancer than the c-erbB-2 promoter and suggest that MK promoter-mediated gene therapy is potentially more favorable in clinical settings.Keywords
This publication has 3 references indexed in Scilit:
- A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovirCancer Gene Therapy, 2001
- Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cellsInternational Journal of Cancer, 2001
- Gene therapy: designer promoters for tumour targetingTrends in Genetics, 2000